Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries
Apixaban (APX) is a direct inhibitor of factor X (FXa) approved for prophylaxis and treatment of deep venous thrombosis and atrial fibrillation. Because FXa activates protease-activated receptor 2 (PAR-2) in endothelium and vascular smooth muscle, inhibition of FXa by APX may affect vasomotor functi...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2017-07-01
|
| Serie: | Frontiers in Pharmacology |
| Soggetti: | |
| Accesso online: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00480/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
